Big Law

Bakers and Clutz advise on pharmaceutical offload (1)

Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital) Deal: NYSE-listed, Canada-based Valeant Pharmaceuticals acquisition of Australian-based iNova…

January 11, 2012 • By Lawyers Weekly

Firms: Baker & McKenzie (Valeant Pharmaceuticals); Clayton Utz (Ironbridge and Archer Capital)

This content is available exclusively to Lawyers Weekly premium members.

INDIVIDUAL

$ 511.50

per

SUBSCRIBE NOW

INDIVIDUAL

Yearly

$ 49.00

per year

SUBSCRIBE NOW

INDIVIDUAL

Monthly

$ 5.00

per month

SUBSCRIBE NOW

Learn more about Premium Benefits and other offers

Username or Email

Password Forgot password?

Keep me signed in on this device.

Deal: NYSE-listed, Canada-based Valeant Pharmaceuticals acquisition of Australian-based iNova Pharmaceuticals from Ironbridge and Archer Capital. Deal officially closed on 21 December

Area: M&A

VIEW ALL

Value: $625 million upfront and up to an additional $75 million in potential milestones

Key players: The Bakers team was led by Sydney-based partner David Egan and associate Michael Dearden

Lawyers Weekly - legal news for Australian lawyers

Bakers and Clutz advise on pharmaceutical offload (1)